{"symbol": "ATNM", "name": "Actinium Pharmaceuticals", "next_earnings_utc": 1591993800, "next_earnings_period_start_date_utc": 1577750400, "next_earnings_period_end_date_utc": 1585612800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.01, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "actiniumpharma.com", "year_founded": 2000, "street_address": "275 Madison Avenue", "city": "New York", "state": "NY", "zipcode": "10016", "country": "United States", "phone_number": "646 677 3870", "short_description": "Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.", "long_description": "Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 64521204, "total_enterprise": 56695493, "number_of_employees": 30, "outstanding_shares": 303343699, "eps": -0.146714, "diluted_eps": -0.146714, "earnings_from_cont_operations": -21899054, "gross_profit": null, "cash": 9253831, "total_debt": 1428120, "total_revenue": null, "cash_from_operations": -21461449, "net_income": -21899054, "ebitda": -21651358, "year_low_stock_price": 0.157, "year_high_stock_price": 0.41, "seekingalpha_follower_count": 6947, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/ATNM.png"}